An immediate release parenteral abuse resistant capsule comprising a parenteral abuse resistant liquid and a shell, the parenteral abuse resistant liquid comprising: (a) an abuse-susceptible active pharmaceutical ingredient selected from the group consisting of opiates, opioids, tranquillizers, stimulants and narcotics; (b) either i) a viscosity enhancer selected from xanthan gum; or ii) at least one ion exchange resin selected from polacrilex resin, sodium polystyrene sulfonate, potassium polyacrilin, and colestyramine resin; (c) a surfactant comprising at least one selected from polysorbate 20, polysorbate 80, macrogolglycerol hydroxystearate, macrogolglycerol ricinoleate, glycerolmonooleate 40, macrogolglycerol linoleate, linoleoyl macrogol-6 glycerides, propylene glycol monolaurate FCC, Lauroglycol FCC, polyglycerol-6-dioleate, polyglycerol-3-dioleate, polyglyceryl-3-oleate, propylene glycol monocaprylate, sorbitan monolaurate, sorbitan monooleate, Vitamin E-polyethylenglycol-succinate, caprylocaproyl macrogol-8 glycerides, macrogol-32-glycerol-laurate, and glycerylmonocaprate/caprylate; (d) a lipophilic carrier selected from medium chain triglycerides, medium chain partial glycerides and a vegetable oil in an amount to dissolve or suspend the active pharmaceutical ingredient, and (e) a stabilizer selected from hard fat, colloidal anhydrous silica and a glycerolester of long chain fatty acid, such that a mixture of 250 to 1000 milligrams of the abuse resistant liquid with 5 milliliters of water at the mixture's boiling point forms a viscous phase, wherein 33% or less of the pharmaceutically active ingredient can be recovered from the viscous phase drawn up into a 25 millimeter needle having an inner diameter of 0.60 millimeters, wherein the capsule releases more than 80% of the active pharmaceutical ingredient within the gastrointestinal tract within 30 minutes of administration. (a) an abuse-susceptible active pharmaceutical ingredient selected from the group consisting of opiates, opioids, tranquillizers, stimulants and narcotics; (b) either i) a viscosity enhancer selected from xanthan gum; or ii) at least one ion exchange resin selected from polacrilex resin, sodium polystyrene sulfonate, potassium polyacrilin, and colestyramine resin; i) a viscosity enhancer selected from xanthan gum; or ii) at least one ion exchange resin selected from polacrilex resin, sodium polystyrene sulfonate, potassium polyacrilin, and colestyramine resin; (c) a surfactant comprising at least one selected from polysorbate 20, polysorbate 80, macrogolglycerol hydroxystearate, macrogolglycerol ricinoleate, glycerolmonooleate 40, macrogolglycerol linoleate, linoleoyl macrogol-6 glycerides, propylene glycol monolaurate FCC, Lauroglycol FCC, polyglycerol-6-dioleate, polyglycerol-3-dioleate, polyglyceryl-3-oleate, propylene glycol monocaprylate, sorbitan monolaurate, sorbitan monooleate, Vitamin E-polyethylenglycol-succinate, caprylocaproyl macrogol-8 glycerides, macrogol-32-glycerol-laurate, and glycerylmonocaprate/caprylate; (d) a lipophilic carrier selected from medium chain triglycerides, medium chain partial glycerides and a vegetable oil in an amount to dissolve or suspend the active pharmaceutical ingredient, and (e) a stabilizer selected from hard fat, colloidal anhydrous silica and a glycerolester of long chain fatty acid, such that a mixture of 250 to 1000 milligrams of the abuse resistant liquid with 5 milliliters of water at the mixture's boiling point forms a viscous phase, wherein 33% or less of the pharmaceutically active ingredient can be recovered from the viscous phase drawn up into a 25 millimeter needle having an inner diameter of 0.60 millimeters, wherein the capsule releases more than 80% of the active pharmaceutical ingredient within the gastrointestinal tract within 30 minutes of administration. <EOS>